INT139064

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 3
Total Number 3
Disease Relevance 1.64
Pain Relevance 1.07

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
T cell 2
CD86 1
Cd80 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
abatacept 6 99.76 Very High Very High Very High
Arthritis 108 98.16 Very High Very High Very High
rheumatoid arthritis 57 96.04 Very High Very High Very High
cytokine 28 85.32 High High
Inflammation 40 84.96 Quite High
metalloproteinase 7 5.00 Very Low Very Low Very Low
chemokine 4 5.00 Very Low Very Low Very Low
antagonist 2 5.00 Very Low Very Low Very Low
methotrexate 2 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Arthritis 112 98.16 Very High Very High Very High
Rheumatoid Arthritis 57 96.04 Very High Very High Very High
Autoimmune Disease 8 86.08 High High
INFLAMMATION 42 84.96 Quite High
General Immunology 1 67.12 Quite High
Organ Transplantation 1 54.64 Quite High
Disease 18 46.00 Quite Low
Apoptosis 13 41.52 Quite Low
Severe Combined Immunodeficiency 8 5.00 Very Low Very Low Very Low
Pressure And Volume Under Development 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CTLA-4Ig fusion protein binds to the co-stimulatory molecules B7-1 and B7-2 present on antigen-presenting cells and blocks CD28/B7 interactions, resulting in decreased T cell activation.
B7-1 Binding (binds) of in T cell
1) Confidence 0.35 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2275302 Disease Relevance 1.03 Pain Relevance 0.52
The selective costimulation inhibitor abatacept (cytotoxic T lymphocyte-associated antigen 4-Ig) binds to CD80 and CD86 on antigen-presenting cells, blocking interaction with CD28 on T cells, and is approved for the treatment of moderate to severe rheumatoid arthritis.
CD80 Binding (binds) of in T cells associated with rheumatoid arthritis and abatacept
2) Confidence 0.11 Published 2008 Journal J. Allergy Clin. Immunol. Section Abstract Doc Link 18269922 Disease Relevance 0.28 Pain Relevance 0.22
The selective costimulation modulator abatacept (CTLA-4Ig) binds to CD80 and CD86, blocking interaction with CD28, and is approved for the treatment of moderate to severe rheumatoid arthritis.
CD80 Binding (binds) of in CD86 associated with rheumatoid arthritis and abatacept
3) Confidence 0.09 Published 2007 Journal Annu. Rev. Med. Section Abstract Doc Link 17020493 Disease Relevance 0.32 Pain Relevance 0.33

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox